Adjustment of the GRACE score by the triglyceride glucose index improves the prediction of clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Shiqiang Xiong†, Qiang Chen†, Xu Chen†, Jun Hou, Yingzhong Chen, Yu Long, Siqi Yang, Lingyao Qi, Hong Su, Wenchao Huang, Hanxiong Liu, Zhen Zhang* and Lin Cai*

Abstract

Background: The Global Registry of Acute Coronary Events (GRACE) score derived from clinical parameters at the time of hospital discharge is a powerful predictor of long-term mortality and reinfarction after acute coronary syndrome (ACS). The triglyceride glucose (TyG) index, which is a simple and reliable surrogate marker of insulin resistance, has been demonstrated to be an independent predictor of long-term adverse major adverse cardiac events, irrespective of diabetes mellitus. We investigate whether the addition of the TyG index improves the predictive ability of the GRACE score after percutaneous coronary intervention (PCI) in ACS patients regardless of diabetes mellitus.

Method: A retrospective cohort of 986 ACS patients undergoing PCI was enrolled in the present analyses. The GRACE score for discharge to 6 months and the TyG index were calculated. The primary endpoint was the composite of MACEs, including all-cause death and nonfatal myocardial infarction. Patients were stratified according to the primary endpoint and the tertiles of the TyG index. Cumulative curves were calculated using the Kaplan–Meier method. Multivariate Cox regression was adopted to identify predictors of MACEs. The predictive value of the GRACE score alone and combined with the TyG index or fasting blood glucose (FBG) was estimated by the area under the receiver-operating characteristic curve, likelihood ratio test, Akaike's information criteria, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Internal validation was assessed using the means of bootstrap method with 1000 bootstrapped samples.

Results: During a median follow-up of 30.72 months (interquartile range, 26.13 to 35.07 months), 90 patients developed MACEs, more frequently in the patients with a higher TyG index. Multivariate Cox hazards regression analysis found that the TyG index, but not FBG was an independent predictor of MACEs (hazard ratio 1.6542; 95% CI 1.1555–2.3681; P = 0.006) in all types of ACS regardless of diabetes mellitus when included in the same model as GRACE.
score. Furthermore, Kaplan–Meier analysis revealed that the incidence of the primary endpoint rose with increasing TyG index tertiles (log-rank, \( P < 0.01 \)). Adjustment the GRACE score by the TyG index improved the predictive ability for MACEs (increase in C-statistic value from 0.735 to 0.744; NRI, 0.282, 95% CI 0.028–0.426, \( P = 0.02 \); IDI, 0.019, 95% CI 0.004–0.046, \( P = 0.01 \)). Likelihood ratio test showed that the TyG index significantly improved the prognostic ability of the GRACE score (\( \chi^2 = 12.37, 1 \text{ df}; P < 0.001 \)). The results remained consistent when the models were confirmed by internal bootstrap validation method.

**Conclusion:** The TyG index, but not FBG is an independent predictor of long-term MACEs after PCI in all types of ACS patients regardless of diabetes mellitus after adjusting for the GRACE score, and improves the ability of the GRACE score to stratify risk and predict prognosis of ACS patients undergoing PCI.

**Keywords:** GRACE score, The triglyceride-glucose index, Acute coronary syndrome, Insulin resistance, Fasting blood glucose, Percutaneous coronary intervention, Major adverse cardiac events, Residual SYNTAX score, Prognosis

**Introduction**
Patients with acute coronary syndrome (ACS) present with diverse clinical characteristics and risk of adverse cardiovascular outcomes. The need to risk stratify ACS patients at discharge for long-term prognosis is widely accepted, which is helpful for making appropriate management decisions. The Global Registry of Acute Coronary Events (GRACE) score derived from clinical parameters at the time of hospital discharge is a powerful predictor of long-term mortality and reinfarction in all types of ACS patients [1–3]. However, some validated predictors associated with unfavorable prognosis have not been included as variables in the GRACE scoring system. Therefore, it is necessary to investigate whether a combination of other prognostic factors with the GRACE score provides a more accurate prognostic assessment and precise yet user-friendly risk stratification in patients with ACS.

The triglyceride glucose (TyG) index, which is a simple, cost-effective, reliable surrogate marker of insulin resistance, has been demonstrated to be associated with an increased risk of cardiovascular diseases in the general population [4–7], and an independent predictor of adverse cardiovascular outcomes after percutaneous coronary intervention (PCI) in different cohorts, irrespective of diabetes [8–13]. To the best of our knowledge, no relevant study has focused on whether the addition of the TyG index improves the predictive ability of the GRACE score in patients with ACS undergoing PCI.

In this study, we investigated the predictive value of the TyG index in addition to GRACE score for major adverse cardiac events (MACEs) after PCI in patients with ACS and the potential incremental prognostic value of adding the TyG index to the GRACE score.

**Methods**

**Study cohort**
We performed a single-center, prospective observational cohort study of consecutive patients with ACS undergoing PCI in the Third People’s Hospital of Chengdu (Sichuan, China) from July 2018 to December 2020. Patients were excluded if (1) they had a history of coronary artery bypass grafting; (2) they had valvular disease and severe mechanical complications requiring cardiac surgery; (3) they had severe hepatic and renal insufficiency (creatinine clearance < 15 ml/min); (6) they suffered from malignant tumors; or (7) they died in hospital. Patients with incomplete key variables including the TyG index variables and GRACE score variables were also excluded. A total of 26 patients were excluded because of missing follow-up data despite at least four separate attempts to contact them. Ultimately, 986 patients were included in the final analyses. This study was approved by the ethics committee of the Third People’s Hospital of Chengdu and strictly complied with the Declaration of Helsinki, with a waiver of patient informed consent. Personal information related to the identities of the participants was concealed.

**Data collection and definitions**
Data on demographics, pervious medical history, smoking, laboratory examination, and medical and procedural information of participants at admission and during hospitalization were obtained from the electronic medical records. Pervious medical histories, such as PCI, chronic obstructive pulmonary disease, hypertension, diabetes mellitus, stroke, and atrial fibrillation were obtained from self-reported information and then confirmed by corresponding medical records. Self-reported diabetes mellitus with the use of antidiabetic medication before hospitalization, or the symptoms of diabetes mellitus with casual blood glucose \( \geq 11.1 \text{ mmol/L}, \) fasting blood glucose (FBG) \( \geq 7.0 \text{ mmol/L}, \) and/or 2-h blood glucose \( \geq 11.1 \text{ mmol/L} \) in the 75g oral glucose tolerance test were the diagnostic criteria for diabetes mellitus [14]. Hypertension was defined as at least three blood pressure measurements \( \geq 140/90 \text{ mmHg} \) [15], and/or currently receiving antihypertensive treatments. ACS was defined

**Keywords:** GRACE score, The triglyceride-glucose index, Acute coronary syndrome, Insulin resistance, Fasting blood glucose, Percutaneous coronary intervention, Major adverse cardiac events, Residual SYNTAX score, Prognosis

**Conclusion:** The TyG index, but not FBG is an independent predictor of long-term MACEs after PCI in all types of ACS patients regardless of diabetes mellitus after adjusting for the GRACE score, and improves the ability of the GRACE score to stratify risk and predict prognosis of ACS patients undergoing PCI.

**Keywords:** GRACE score, The triglyceride-glucose index, Acute coronary syndrome, Insulin resistance, Fasting blood glucose, Percutaneous coronary intervention, Major adverse cardiac events, Residual SYNTAX score, Prognosis

**Introduction**
Patients with acute coronary syndrome (ACS) present with diverse clinical characteristics and risk of adverse cardiovascular outcomes. The need to risk stratify ACS patients at discharge for long-term prognosis is widely accepted, which is helpful for making appropriate management decisions. The Global Registry of Acute Coronary Events (GRACE) score derived from clinical parameters at the time of hospital discharge is a powerful predictor of long-term mortality and reinfarction in all types of ACS patients [1–3]. However, some validated predictors associated with unfavorable prognosis have not been included as variables in the GRACE scoring system. Therefore, it is necessary to investigate whether a combination of other prognostic factors with the GRACE score provides a more accurate prognostic assessment and precise yet user-friendly risk stratification in patients with ACS.

The triglyceride glucose (TyG) index, which is a simple, cost-effective, reliable surrogate marker of insulin resistance, has been demonstrated to be associated with an increased risk of cardiovascular diseases in the general population [4–7], and an independent predictor of adverse cardiovascular outcomes after percutaneous coronary intervention (PCI) in different cohorts, irrespective of diabetes [8–13]. To the best of our knowledge, no relevant study has focused on whether the addition of the TyG index improves the predictive ability of the GRACE score in patients with ACS undergoing PCI.

In this study, we investigated the predictive value of the TyG index in addition to GRACE score for major adverse cardiac events (MACEs) after PCI in patients with ACS and the potential incremental prognostic value of adding the TyG index to the GRACE score.

**Methods**

**Study cohort**
We performed a single-center, prospective observational cohort study of consecutive patients with ACS undergoing PCI in the Third People’s Hospital of Chengdu (Sichuan, China) from July 2018 to December 2020. Patients were excluded if (1) they had a history of coronary artery bypass grafting; (2) they had valvular disease and severe mechanical complications requiring cardiac surgery; (3) they had severe hepatic and renal insufficiency (creatinine clearance < 15 ml/min); (6) they suffered from malignant tumors; or (7) they died in hospital. Patients with incomplete key variables including the TyG index variables and GRACE score variables were also excluded. A total of 26 patients were excluded because of missing follow-up data despite at least four separate attempts to contact them. Ultimately, 986 patients were included in the final analyses. This study was approved by the ethics committee of the Third People’s Hospital of Chengdu and strictly complied with the Declaration of Helsinki, with a waiver of patient informed consent. Personal information related to the identities of the participants was concealed.

**Data collection and definitions**
Data on demographics, pervious medical history, smoking, laboratory examination, and medical and procedural information of participants at admission and during hospitalization were obtained from the electronic medical records. Pervious medical histories, such as PCI, chronic obstructive pulmonary disease, hypertension, diabetes mellitus, stroke, and atrial fibrillation were obtained from self-reported information and then confirmed by corresponding medical records. Self-reported diabetes mellitus with the use of antidiabetic medication before hospitalization, or the symptoms of diabetes mellitus with casual blood glucose \( \geq 11.1 \text{ mmol/L}, \) fasting blood glucose (FBG) \( \geq 7.0 \text{ mmol/L}, \) and/or 2-h blood glucose \( \geq 11.1 \text{ mmol/L} \) in the 75g oral glucose tolerance test were the diagnostic criteria for diabetes mellitus [14]. Hypertension was defined as at least three blood pressure measurements \( \geq 140/90 \text{ mmHg} \) [15], and/or currently receiving antihypertensive treatments. ACS was defined
as including either unstable angina (UA), ST segment elevation myocardial infarction (STEMI), or non-ST segment elevation myocardial infarction (NSTEMI) [16].

Peripheral venous blood was sampled from patients after overnight fasting (> 8h). Venous plasma concentrations of total cholesterol (TC), triglycerides (TG), low-density lipoprotein-C (LDL-C), high-density lipoprotein-C (HDL-C), FBG, serum creatinine, brain natriuretic peptide (BNP), and cardiac troponin T (cTnT) were determined by standard biochemical techniques. The two-dimensional modified Simpson's method was used to determine the left ventricular ejection fraction (LVEF).

Calculation of the TyG index, GRACE score, and baseline and residual SYNTAX score

In brief, the TyG index is derived from fasting TG and FBG, and was calculated as: \( \ln \left[ \frac{\text{fasting TG (mg/dL)} \times \text{FBG (mg/dL)}}{2} \right] \) [17]. The web-based GRACE score calculator was used to calculate the risk of 6-month mortality or MI for each individual [1]. The GRACE score was originally designed to calculate the risk of mortality or MI from discharge to 6 months and has been shown to provide good discrimination of mortality and MI up to 4 years after an ischemic event [2, 18]. A web-based online calculation tool (http://syntaxscore.com/) was used to calculate the baseline SYNTAX score (bSS) from the preprocedural angiograms by two independent operators who were blinded to baseline clinical characteristics and clinical outcomes. The residual SYNTAX score (rSS) was calculated based on other obstructive coronary disease cases after treatment with PCI [19]. In the case of staged PCI procedures, the rSS after the last planned revascularization was used as the entry point for final analysis. In case of disagreement, the opinion of the third operator was obtained and the decision was made by consensus. A level of rSS greater than 8 was defined as incomplete revascularization. All data were entered into a dedicated computer database and assessed for quality.

Follow-up and endpoints

Clinical follow-up was scheduled at 1, 3, 6, and 12 months, and then every 6 months after hospital discharge by telephone contact or outpatient clinical visits. Follow-up clinical events were investigated and recorded by well-trained professionals. The primary endpoint was major adverse cardiac events (MACEs), defined as a composite of all-cause death and nonfatal MI. Secondary endpoints included cardiac death, unplanned revascularization, and nonfatal stroke. All clinical endpoints were further confirmed by referring to corresponding medical records as necessary. All-cause death referred to death regardless of the cause. MI was defined as elevated creatine kinase or cardiac troponin greater than the upper limit of the normal range with ischemia indicated from electrocardiographic changes and/or symptoms. Unplanned revascularization was defined as any ischemia-driven target or nontarget revascularization after the index PCI during the follow-up period. Stroke was defined as an ischemic or hemorrhagic stroke as demonstrated by the evidence of neurological dysfunction or clinically documented lesions on imaging.

Statistical analysis

Categorical variables are presented as numbers and percentages. Continuous variables are expressed as the mean and SD or median and interquartile range. ANOVA test or the Kruskal-Wallis test was used as appropriate. Study participants were stratified into three groups based on the TyG index tertiles. The cumulative incidence of clinical outcomes was assessed using the Kaplan-Meier method and determined by the log-rank test. The hazard ratio (HR) with 95% confidence interval (CI) of developing the primary endpoint was estimated by the Cox proportional regression model. Both the TyG index and GRACE score were analyzed as continuous variables. Variables identified through univariate analysis with P values < 0.10 were selected for multivariate analysis.

The χ² likelihood ratio tests were used to estimate whether the addition of the TyG index or FBG to the logistic regression model that included the GRACE score provided a significantly better fit. Comparison of nested and non-nested models including the GRACE score, or its combination with the TyG index or FBG was performed by calculating corrected Akaike’s information criterion (AICc), delta-AICc (δAICc), and AICc weights (AICcWt) to determine the adequacy that a given model was the best fitting one of those studied [20].

The optimism for different models was determined by internal validation using the means of bootstrap method (with 1000 bootstrapped samples) with the relatively corrected C-index. The differences in performance indicated the expected optimism, which were calculated by subtracting the optimism from the apparent model performance [21]. Calibration curves, which describe the calibration of the model in terms of the agreement between the predicted risks of adverse cardiovascular events and observed frequency of adverse cardiovascular events, were also adopted to estimate the model performance [22]. The y-axis represents the actual adverse cardiovascular events rate. The x-axis represents the predicted adverse cardiovascular events risk. The grey line indicates a perfect prediction by an ideal model. The red solid line indicates the performance of the predicting model, of which a closer fit to the grey line suggests better prediction.
The area under the receiver operating characteristic (ROC) curves was adopted to identify the predictive value of different parameters or risk models for clinical outcomes. The incremental predictive value from adding the TyG index or FBG to the GRACE score to predict clinical outcomes was analyzed from these predicted probabilities using several measures of improvement in discrimination: C-statistics, net reclassification improvement (NRI) and integrated discrimination improvement (IDI). All tests were 2-sided, and P < 0.05 was considered statistically significant.

All statistical analyses were conducted using SPSS version 26.0 software (IBM Corporation, Chicago, IL, USA) and R version 4.0.2 software (Vienna, Austria).

**Results**

**Baseline characteristics**

A total of 986 patients (66.61 ± 11.42 years, 28.3% female) who presented with ACS and completed the follow-up were available for the final analysis. During a median follow-up of 30.72 months (IQR, 26.13 to 35.07 months), there were 90 MACEs (9.13%). The baseline characteristics of the total population are summarized in Table 1. All patients were stratified into three groups [T1 (TyG index > 9.24), T2 (8.65 < TyG index ≤ 9.24), and T3 (TyG index ≤ 8.65)] in accordance with tertiles of the TyG index (Table 1). The mean TyG index values of the three groups were 8.28 ± 0.29, 8.96 ± 1.73, and 9.79 ± 0.47, respectively. Compared with patients in the tertile 1 group, patients with a higher TyG index tended to be younger, female, had a higher prevalence of diabetes mellitus, ST-segment depression, multivessel disease and incomplete revascularization, higher levels of body mass index, FBG, TG, TC, LDL-C, bSS, and rSS, a lower level of HDL-C, and used more insulin and oral hypoglycemic agents at discharge.

**The predictive value of the TyG index and GRACE score for adverse cardiovascular events**

During the 30.72-month (IQR, 26.13 to 35.07 months) follow-up, 90 (9.13%) MACEs were recorded (Table 2), including 66 (6.69%) all-cause deaths, 40 (4.06%) cardiac deaths, 26 (2.64%) nonfatal MIs, 99 (10.04%) unplanned revascularizations, and 37 (3.75%) strokes. The rate of MACEs, all-cause deaths, cardiac deaths, and unplanned revascularizations increased progressively with a higher TyG index.

Kaplan-Meier survival curves of the incidence of the primary endpoint and each clinical event for the TyG index tertiles are shown in Fig. 1. The incidence of the primary endpoint (MACEs) increased progressively with a higher TyG index (log-rank test, P < 0.01, Fig. 1A). This difference was mainly driven by the increase in all-cause deaths (log-rank test, P < 0.01, Fig. 1B). The incidence of cardiac deaths and unplanned revascularizations also increased with higher tertiles of the TyG index (Fig. 1C, D). However, the incidence of MIs and strokes at follow-up were similar among the TyG index tertiles (Fig. 1E, F).

The GRACE score, TyG index, female, bSS, ICR, LVEF, AMI, β-blocker, and diuretics were entered into the multivariate Cox regression analysis. The TyG index and GRACE score were introduced into multivariate Cox regression analysis as a continuous variable, and after adjustment for multiple confounding factors, an increased TyG index and/or GRACE score were associated with a higher risk of MACEs (HR 1.6028, 95% CI 1.1900–2.1588, P = 0.0019; 1.0202, (95% CI 1.0117–1.0288), P < 0.0001) in patients with ACS undergoing PCI (Table 3). On Cox proportional hazard regression analysis neither FBG nor TG was an independent predictor of MACEs at the final follow-up when included in the same model as GRACE score (Additional file 1: Table S1).

The area under the ROC curve (AUC) of the TyG index was significantly better than that of TG [0.607 (95% CI: 0.576–0.638) vs. 0.563 (95% CI: 0.532–0.594), P = 0.0182], but was not significantly greater than that of FBG [0.607 (95% CI: 0.576–0.638) vs. 0.586 (95% CI: 0.554–0.617), P = 0.4725] (Fig. 2A–C) (Additional file 1: Tables S2, S3). The AUC of the GRACE score for predicting MACEs was 0.723 (95% CI: 0.694–0.750, P < 0.001) (Fig. 2D). Taken together, we demonstrate that the TyG index, but neither FBG nor TG, independently predicts prognosis after PCI for patients with ACS after adjusting for the GRACE score.

**The predictive value of the TyG index for MACE in various subgroups**

Various subgroup analyses were also performed to investigate whether the predictive value of the TyG index was similar among patients with different demographic characteristics or comorbidities (Fig. 3). We found that the TyG index was a significant predictor of MACEs regardless of current smoking, diabetes mellitus, NSTE-ACS (unstable angina + NSTEMI) or STEMI. The predictive value of the TyG index was more prominent in males, and patients with age > 65 years, hypertension, or incomplete revascularization.

**The incremental predictive value of the TyG index for MACEs**

The model performance after the addition of the TyG index to the baseline GRACE score in patients with ACS undergoing PCI is presented in Tables 4 and 5. The results of the likelihood ratio tests showed that addition of the TyG index as a continuous variable significantly improved the ability of the baseline GRACE
Table 1  Baseline characteristics of the patients stratified by the TyG index tertiles

| Variable                      | T1 (n = 332)      | T2 (n = 327)      | T3 (n = 327)      | P value |
|-------------------------------|-------------------|-------------------|-------------------|---------|
| **GRACE variables**           |                   |                   |                   |         |
| Age, years                    | 68.10 ± 11.89     | 66.65 ± 10.95     | 65.07 ± 11.24     | 0.003   |
| SBP, mmHg                     | 131.28 ± 19.81    | 133.17 ± 22.69    | 132.25 ± 21.66    | 0.525   |
| h, bpm                        | 76.15 ± 14.41     | 78.15 ± 14.95     | 78.66 ± 14.96     | 0.071   |
| Serum creatinine, umol/L      | 77.60 (65.55, 90.75) | 78.10 (66.80, 92.70) | 73.20 (61.10, 90.20) | 0.046   |
| CHF, n (%)                    | 125 (37.7)        | 128 (39.1)        | 142 (43.4)        | 0.292   |
| Previous MI, n (%)            | 15 (4.5)          | 21 (6.4)          | 17 (5.2)          | 0.548   |
| ST-segment depression, n (%)  | 129 (38.9)        | 124 (37.9)        | 155 (47.4)        | 0.025   |
| Elevated cardiac enzymes/markers, n (%) | 210 (63.3) | 221 (67.6) | 232 (70.9) | 0.108   |
| **GRACE score**               | 110.61 ± 31.99    | 109.54 ± 29.91    | 109.30 ± 32.31    | 0.851   |
| the TyG index                 | 8.28 ± 0.29       | 8.96 ± 1.73       | 9.79 ± 0.47       | <0.001  |
| Female, n (%)                 | 72 (21.7)         | 83 (25.4)         | 124 (37.9)        | <0.001  |
| BMI, kg/m^2                   | 23.58 ± 2.89      | 24.61 ± 2.78      | 24.77 ± 2.78      | <0.001  |
| Smoking, n (%)                | 181 (54.5)        | 187 (57.2)        | 173 (52.9)        | 0.539   |
| Previous PCI, n (%)           | 30 (9.0)          | 29 (8.9)          | 24 (7.3)          | 0.689   |
| COPD, n (%)                   | 22 (6.6)          | 20 (6.1)          | 13 (4.0)          | 0.291   |
| Hypertension, n (%)           | 208 (62.7)        | 217 (66.4)        | 214 (65.4)        | 0.582   |
| Diabetes mellitus, n (%)      | 49 (14.8)         | 105 (32.1)        | 189 (57.8)        | <0.001  |
| AF, n (%)                     | 27 (8.1)          | 20 (6.1)          | 19 (5.8)          | 0.431   |
| Previous Stroke, n (%)        | 25 (7.5)          | 27 (8.3)          | 23 (7.0)          | 0.839   |
| **Laboratory measurements**   |                   |                   |                   |         |
| cTnT, pg/mL                   | 28.29 (10.73, 968.00) | 30.10 (11.84, 652.60) | 59.25 (13.36, 1006.60) | 0.233   |
| BNP, pg/mL                    | 109.85 (45.03, 301.08) | 103.50 (32.60, 287.30) | 111.60 (38.10, 324.00) | 0.337   |
| FBG (mmol/L)                  | 5.39 ± 1.18       | 6.41 ± 1.82       | 9.19 ± 4.03       | <0.001  |
| TG (mmol/L)                   | 0.97 ± 0.28       | 1.63 ± 0.44       | 2.96 ± 1.68       | <0.001  |
| TC (mmol/L)                   | 4.07 ± 1.07       | 4.50 ± 1.24       | 4.85 ± 1.23       | <0.001  |
| HDL-C (mmol/L)                | 1.22 ± 0.33       | 1.14 ± 0.28       | 1.10 ± 0.27       | <0.001  |
| LDL-C (mmol/L)                | 2.47 ± 0.81       | 2.81 ± 0.92       | 3.22 ± 2.86       | <0.001  |
| LVEF                          | 55.16 ± 8.81      | 55.33 ± 8.74      | 54.22 ± 9.28      | 0.231   |
| Diagnosis, n (%)              |                   |                   |                   | 0.262   |
| UA                            | 165 (49.7)        | 157 (48.0)        | 143 (43.7)        |         |
| NSTEMI                         | 62 (18.7)         | 77 (23.5)         | 82 (25.1)         |         |
| STEMI                          | 105 (31.6)        | 93 (28.4)         | 102 (31.2)        |         |
| **Angiographic data**         |                   |                   |                   |         |
| MVD, n (%)                    | 202 (60.8)        | 228 (69.7)        | 239 (73.1)        | 0.002   |
| LM, n (%)                     | 11 (3.3)          | 23 (7.0)          | 20 (6.1)          | 0.091   |
| Calcified lesions, n (%)      | 42 (12.7)         | 44 (13.5)         | 50 (15.3)         | 0.603   |
| Thrombosis, n (%)             | 20 (60.0)         | 28 (8.6)          | 31 (9.5)          | 0.238   |
| Long lesion, n (%)            | 131 (39.5)        | 153 (46.8)        | 170 (52.0)        | 0.005   |
| CTO, n (%)                    | 54 (16.3)         | 82 (25.1)         | 67 (20.5)         | 0.020   |
| Number of stents              | 1.35 ± 0.77       | 1.47 ± 0.91       | 1.56 ± 0.94       | 0.008   |
| Length of stents, mm          | 35.12 ± 23.70     | 38.71 ± 27.56     | 41.51 ± 28.00     | 0.008   |
| bSS                           | 11.00 (7.00, 18.00) | 14.00 (8.00, 21.00) | 14.50 (8.50, 20.50) | <0.001  |
| rSS                           | 2.00 (0.00, 6.00) | 3.00 (0.00, 7.50) | 3 (0.00, 8.00) | 0.010   |
| ICR, n (%)                    | 198 (59.6)        | 220 (67.3)        | 236 (72.2)        | 0.003   |
| **Discharge medications**     |                   |                   |                   |         |
| Aspirin, n (%)                | 322 (97.0)        | 320 (97.9)        | 319 (97.6)        | 0.770   |
| P2Y12 receptor inhibitor, n (%) | 328 (98.8) | 324 (99.1) | 322 (98.5) | 0.775   |
| Statins, n (%)                | 321 (96.7)        | 319 (97.6)        | 319 (97.6)        | 0.733   |
score to predict MACEs (Table 4). Addition of FBG did not improve the model fit. Comparing the baseline GRACE score alone, GRACE score with the TyG index and GRACE score with FBG, the former yielded the lowest corrected AIC compared to that with only GRACE score (Table 4). This indicates that the model with GRACE score and the TyG index is more likely to be the best fitting model compared with the other models tested.

Compared with the baseline GRACE score for predicting MACEs, the addition of the TyG index had a significant increase in the C-statistic from 0.735 (95% CI 0.682–0.788) to 0.744 (95% CI 0.689–0.800) (P < 0.01), and significant improvement in reclassification as assessed by the NRI (0.282, 95% CI 0.028–0.426, P = 0.02) and IDI (0.019, 95% CI 0.004–0.046, P = 0.01) (Fig. 4A). Moreover, the addition of the TyG index also has an incremental predictive value for predicting other adverse cardiovascular events in terms of all-cause death, cardiac death, and all-cause death, MI or unplanned revascularization. The calibration plots for adverse cardiovascular events showed good agreement between the actual observation and the predicted possibility (Fig. 5).

Discussion
This study shows that the TyG index, neither FBG nor TG, independently predicts prognosis after PCI in patients with ACS regardless of diabetes mellitus after adjusting for the GRACE score. The addition of the TyG index improved the ability of the GRACE score to predict long-term adverse cardiovascular events in patients with

Table 1 (continued)

| Variable               | T1 (n = 332) | T2 (n = 332) | T3 (n = 332) | P value |
|------------------------|-------------|-------------|-------------|---------|
| β-blockers, n (%)      | 218 (65.7)  | 231 (70.6)  | 238 (72.8)  | 0.124   |
| ACEI/ARB, n (%)        | 132 (39.8)  | 149 (45.6)  | 135 (41.3)  | 0.295   |
| Diuretics, n (%)       | 50 (15.1)   | 50 (15.3)   | 51 (15.6)   | 0.982   |
| Insulin, n (%)         | 4 (1.2)     | 20 (6.1)    | 46 (14.1)   | <0.001  |
| Oral hypoglycemic agents, n (%) | 22 (6.6) | 77 (23.5)   | 123 (37.6)  | <0.001  |

The patients were divided into three groups in accordance with tertiles of the TyG index [T1 (TyG index ≤ 8.65), T2 (8.65 < TyG index ≤ 9.24), and T3 (TyG index > 9.24)]. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; SBP, systolic blood pressure; HR, heart rate; CHF, congestive heart failure; BNP, brain natriuretic peptide; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; LVEF, left ventricular ejection fraction; UA, unstable angina; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; MVD, multivessel disease; LM, left main disease; CTO, chronic total occlusion; bSS, baseline SYNTAX score; rSS, residual SYNTAX score; ICR, incomplete revascularization; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Data are presented as the mean ± SD, median (IQR) or n (%).

Table 2

| Variable               | Total (n = 986) | T1 (n = 332) | T2 (n = 332) | T3 (n = 332) | P value |
|------------------------|----------------|-------------|-------------|-------------|---------|
| MACEs, n (%)           | 90 (9.13)      | 20 (6.02)   | 27 (8.26)   | 43 (13.15)  | 0.005   |
| All-cause death, n (%) | 66 (6.69)      | 14 (4.22)   | 16 (4.89)   | 36 (11.01)  | 0.001   |
| Cardiac death, n (%)   | 40 (4.06)      | 8 (2.41)    | 11 (3.36)   | 21 (6.42)   | 0.025   |
| Myocardial infarction, n (%) | 26 (2.64) | 6 (1.81)    | 11 (3.36)   | 9 (2.75)    | 0.454   |
| Unplanned revascularization, n (%) | 99 (10.04) | 24 (7.23)   | 30 (9.17)   | 45 (13.76)  | 0.017   |
| Stroke, n (%)          | 37 (3.75)      | 11 (3.31)   | 15 (4.59)   | 11 (3.36)   | 0.624   |

The patients were divided into three groups in accordance with tertiles of the TyG index [T1 (TyG index ≤ 8.65), T2 (8.65 < TyG index ≤ 9.24), and T3 (TyG index > 9.24)]. MACEs indicate major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction.
Fig. 1 Cumulative incidence of the incidence of primary endpoint and each clinical event according to the TyG index tertiles. Kaplan-Meier curves for the incidence of MACEs (A), all-cause death (B), cardiac death (C), unplanned repeat revascularization (D), nonfatal myocardial infarction (E), and nonfatal stroke (F) among the 3 study groups based on the TyG index tertiles. TyG indicates triglyceride–glucose.
ACS undergoing PCI. Our findings support the addition of the TyG index to the model containing the GRACE score to improve the predictive value for predicting long-term adverse cardiovascular events, thus assisting clinicians in management decisions in ACS patients.

Early identification of ACS patients undergoing PCI who have a high residual risk for poor prognosis is crucial for making better management decisions to reduce future cardiovascular events. It is well acknowledged that clinical management decisions in ACS should be made on risk stratification [23]. The GRACE score has been widely accepted as a powerful predictor of adverse cardiovascular outcomes after ACS and provides validated prognostic information at different time points up to 4 years [1–3]. In line with previous research results, the GRACE score independently predicted long-term MACEs after PCI in our ACS patients, regardless of diabetes mellitus. The AUC with the GRACE score was only 0.723, which might be affected by some potential risk factors not included in the scoring model. Growing evidence demonstrates that the TyG index in the general population and in patients with coronary artery disease, regardless of diabetes mellitus is an independent prognostic factor of adverse cardiovascular outcomes [4–6, 8–13, 24]. It is worth noting that variables required for the TyG index calculation are widely available, and insulin resistance appears to be a potentially modifiable risk and therapeutic target. However, the TyG index has not been included in the GRACE scoring system in a previous study.

Several previous studies have identified some potential risk factors combined with the GRACE score, which attempted to enhance the predictive ability for adverse clinical outcomes after ACS, such as nutritional risk index [25], neutrophil count [26], B-type natriuretic peptide [27], 2-hour postload glucose [28], and hemoglobin A1c [23]. The populations enrolled in the above studies were patients with STEMI or nondiabetic patients with ACS. Whether the addition of these risk factors improves the predictive ability of GRACE score in all types of ACS regardless of diabetes mellitus was not validated. In our ACS patients, we found that both the GRACE score and TyG index were significant predictors of MACEs. Adjustment of the GRACE score by the TyG index on admission enhanced the predictive ability for MACEs after PCI in all types of ACS patients irrespective of diabetes mellitus (AUC increased from 0.723 for GRACE score alone to 0.737 for GRACE score plus the TyG index, P < 0.01). Although improving risk-prediction models containing powerful variables such as the GRACE score may be difficult, a large improvement in net reclassification was achieved (NRI, 0.282, 95% CI 0.028–0.426, P = 0.02) when adding the TyG index to the GRACE score.
results indicate that this new risk-prediction model might be applicable to all types of ACS, which would provide a more accurate prognostic assessment in clinical practice. Achieving complete revascularization is a desired goal of PCI in patients with coronary artery disease. Previous studies have documented that complete revascularization is more beneficial than incomplete revascularization, while residual lesions are associated with poor long-term prognosis after PCI [19, 29, 30]. However, for patients with complex coronary artery lesions, complete revascularization cannot always be achieved. In the present study, 66.3% of the patients had greater anatomic complexity and incomplete revascularization. The TyG index was an independent predictor of long-term MACEs after

Fig. 2 ROC curve analysis evaluating the diagnostic performance for MACEs in ACS patients undergoing PCI. A The area under the curve (AUC) of the TyG index for predicting MACEs was 0.607 (95% CI: 0.576–0.638, P = 0.001). B The AUC of the FBG for predicting MACEs was 0.586 (95% CI: 0.554–0.617, P = 0.005). The AUC of the TG for predicting MACEs was 0.563 (95% CI: 0.532–0.594, P = 0.0039). The AUC of the GRACE score for predicting MACEs was 0.723 (95% CI: 0.694–0.750, P < 0.001). ROC, receiver operating characteristic; ACS, acute coronary syndrome; MACEs, major adverse cardiac events; PCI, percutaneous coronary intervention; TyG, triglyceride-glucose; FBG, fasting blood glucose; TG, triglyceride.
PCI in ACS patients with incomplete revascularization. Our findings highlight the importance of achieving a reasonable level of revascularization and providing more targeted treatment for ACS patients undergoing PCI, especially those with high residual risk for adverse clinical outcomes.

Limitations
This study was a retrospective analysis derived from a single-center prospective observational study limited by its post hoc nature. Whether the combination of the TyG index and GRACE score improves the clinical outcomes of ACS patients undergoing PCI warrants further comprehensive investigation. The baseline level of the TyG index was derived from triglycerides and FPG on admission, which could be affected by the use of lipid-lowering and antidiabetic medications during the follow-up period. Whether the fluctuation of the TyG index impacts its predictive ability on the prognosis in patients with ACS undergoing PCI requires further investigation. Clinical trials are also needed to confirm whether improving IR can improve clinical outcomes in these patients. Finally, the results have not been externally validated. Internal validity was evaluated by the means of bootstrap with a 1000-bootstrap resampling strategy and the results demonstrated good

### Table 4

Akaike's information criteria and likelihood ratio test to determine the best fitting model for predicting MACEs

| Model                      | AICc  | δAICc | AICcWt | Cum.wt | Model χ² | df | P value |
|----------------------------|-------|-------|--------|--------|----------|----|---------|
| GRACE score                | 1098.73 | 10.35 | 0.99   | 0.99   | 0.99     | 1  | <0.001  |
| GRACE score + TyG index    | 1088.38 | 0.00  | 1.00   | 1.00   | 1.00     | 1  | <0.001  |
| GRACE score + FBG          | 1100.47 | 12.09 | 0.00   | 1.00   | 0.27     | 1  | 0.604   |

MACEs indicates major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; FBG, fasting blood glucose; AICc, corrected Akaike's information criterion; δAICc, delta-AICc; AICcWt, AICc weights; Cum.wt, the cumulative weights of AIC.
Table 5 Evaluation the incremental prognostic value of adding the TyG index to the GRACE score to predict clinical outcomes

|                         | C-index (95% CI) | P value | NRI (95% CI) | P value | IDI (95% CI) | P value |
|-------------------------|-----------------|---------|--------------|---------|--------------|---------|
| **MACEs**               |                 |         |              |         |              |         |
| GRACE score             | 0.735 (0.682, 0.788) | < 0.01  | Ref.         | Ref.    | Ref.         | Ref.    |
| GRACE score + FBG       | 0.735 (0.681, 0.789) | < 0.01  | 0.068 (0.165, 0.248) | 0.50    | 0.001 (0.001, 0.013) | 0.39    |
| GRACE score + TyG index | 0.744 (0.688, 0.800) | < 0.01  | 0.282 (0.028, 0.426) | 0.02    | 0.019 (0.004, 0.046) | 0.01    |
| **All-cause death**     |                 |         |              |         |              |         |
| GRACE score             | 0.750 (0.690, 0.810) | < 0.01  | Ref.         | Ref.    | Ref.         | Ref.    |
| GRACE score + FBG       | 0.753 (0.694, 0.812) | < 0.01  | 0.085 (−0.193, 0.203) | 0.41    | 0.002 (−0.001, 0.025) | 0.39    |
| GRACE score + TyG index | 0.765 (0.704, 0.826) | < 0.01  | 0.308 (0.017, 0.445) | 0.03    | 0.026 (0.004, 0.053) | <0.01  |
| **Cardiac death**       |                 |         |              |         |              |         |
| GRACE score             | 0.776 (0.708, 0.844) | < 0.01  | Ref.         | Ref.    | Ref.         | Ref.    |
| GRACE score + FBG       | 0.776 (0.708, 0.844) | < 0.01  | 0.079 (−0.145, 0.241) | 0.49    | 0.000 (−0.001, 0.019) | 0.52    |
| GRACE score + TyG index | 0.785 (0.714, 0.856) | < 0.01  | 0.336 (0.031, 0.485) | 0.01    | 0.015 (0.003, 0.047) | <0.01  |
| **All-cause death, MI, or unplanned revascularization** | | | | | |
| GRACE score             | 0.655 (0.609, 0.701) | < 0.01  | Ref.         | Ref.    | Ref.         | Ref.    |
| GRACE score + FBG       | 0.658 (0.612, 0.704) | < 0.01  | 0.099 (−0.067, 0.231) | 0.23    | 0.002 (0.000, 0.009) | 0.20    |
| GRACE score + TyG index | 0.673 (0.626, 0.720) | < 0.01  | 0.267 (0.106, 0.418) | < 0.01  | 0.017 (0.005, 0.035) | <0.01  |

MACEs indicates major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; MI, myocardial infarction; CI, confidence interval; NRI, net reclassification improvement; IDI, integrated discrimination improvement.

Fig. 4 ROC curve analysis of the model performance after adding the TyG index to the baseline GRACE score. The areas under the ROC curves were used to compare the predictive ability between the baseline GRACE score and the TyG index plus the GRACE score for MACEs (A), all-cause death (B), cardiac death (C), and all-cause death, MI, or unplanned revascularization (D). ROC, receiver operating characteristic; TyG, triglyceride-glucose; MACEs, major adverse cardiac events; MI, myocardial infarction.
performance in terms of discrimination and calibration for predicting risk of adverse cardiovascular events in ACS patients undergoing PCI.

Conclusion
The TyG index was an independent prognostic predictor of long-term adverse outcomes after PCI in all types of ACS patients, irrespective of diabetes mellitus, after adjusting for the GRACE score. The TyG index improves the ability of the GRACE score to stratify risk and predict prognosis of ACS patients undergoing PCI. Whether the combination of the TyG index and GRACE score improves the prognosis of ACS patients undergoing PCI by aiding in more accurate prognostic assessment and better clinical management decisions warrants further investigation.

Abbreviations
MACEs: Major adverse cardiac events; GRACE score: The Global Registry of Acute Coronary Events score; IR: Insulin resistance; BMI: Body mass index; PCI: Percutaneous coronary intervention; COPD: Chronic obstructive pulmonary disease; AF: Atrial fibrillation; SBP: Systolic blood pressure; HR: Heart rate; BNP: Brain natriuretic peptide; FBG: Fasting blood glucos; TG: Triglyceride; TC: Total cholesterol; HDL: High density lipoprotein-C; LDL: Low density lipoprotein-C; LVEF: Left ventricular ejection fraction; ACS: Acute coronary syndrome; MI: Myocardial infarction; ACEI/ARB: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker; MVD: Multivessel disease; LM: Left main disease; CTO: Chronic total occlusion; ROC: Receiver operating characteristic; TyG: Triglyceride-glucose; bSS: Baseline SYNTAX score; rSS: Residual SYNTAX score; NRI: Continuous net reclassification improvement; IDI: Integrated discrimination improvement.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01582-w.

Additional file 1: Table S1. Univariate and multivariate Cox regression analysis for predicting the primary endpoint. Table S2. The ROC curve analysis of the GRACE score, the TyG index, FBG and TG for MACEs. Table S3.
The comparison of model performance. Table S4. The model performance estimated by internal bootstrap validation method.

Acknowledgements
We thank Tao Ye, Minjian Peng, and Long Xia (Department of Cardiology, the Third People’s Hospital of Chengdu) who calculated the bSS and rSS.

Author contributions
SX drafted the manuscript. SX, QC, and XC were major contributors in the collection, analysis and interpretation of data. JH, YC, YL, SY, LQ, HS, and WH collected the patient data, and were major contributors in the management of follow-up. ZZ put forward constructive comments and suggestions, and revised the manuscript for important intellectual content. LC designed the study, and finally approved the manuscript submitted. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81660042), and Chengdu High-level Key Clinical Specialty Construction Project.

Availability of data and materials
The datasets used and/or analyzed in the study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the ethics committee of the Third People’s Hospital of Chengdu and strictly complied with the Declaration of Helsinki. The study was approved by the ethics committee of the Third People’s Hospital of Chengdu and finally approved the manuscript submitted. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the ethics committee of the Third People’s Hospital of Chengdu and strictly complied with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 26 June 2022   Accepted: 25 July 2022
Published online: 05 August 2022

References
1. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA Jr, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.
2. Tang EW, Wong CK, Herbst P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153(1):29–35.
3. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. Jama. 2004;291(2):2727–33.
4. Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S, Wang A. Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20(1):19.
5. Wang A, Tian X, Zuo Y, Chen S, Meng X, Wu S, Wang Y. Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study. Cardiovasc Diabetol. 2021;20(1):113.
6. Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, Shi S. The role of the triglyceride (triaclyglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci Rep. 2019;9(1):7320.
7. Park B, Lee YJ, Lee HS, Jung OH. The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: a prospective study using National Health Insurance Service data. Cardiovasc Diabetol. 2020;19(1):210.
8. Luo E, Wang D, Yan G, Qiao Y, Liu B, Hou J, Tang C. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18(1):150.
9. Zhao Q, Cheng YJ, Xu YK, Zhao ZW, Liu C, Sun TN, Zhou YJ. Compari- son of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):190.
10. Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, Zhou YJ. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. Cardiovasc Diabetol. 2020;19(1):108.
11. Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, Yang H, Ren LB, Qi W, Li YW, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.
12. Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, Shen H, Wang Z, Zhou Y, Liu X. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):31.
13. Yang J, Tang Y-D, Zheng Y, Li C, Zhou Q, Gao J, Meng X, Zhang K, Wang W, Shao C. The Impact of the Triglyceride-Glucose Index on Poor Prognosis in NonDiabetic Patients Undergoing Percutaneous Coronary Intervention. Front Endocrinol. 2021;12:78.
14. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020,43.
15. Aronow WS. Hypertension guidelines. Hypertension. 2011;58(3):347–8.
16. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA. 2000;284(7):876–8.
17. Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SQ, Jacques-Cama-rena Q, Rodriguez-Moran M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51.
18. Eagle KA, Lip D, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Good- man SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA. A Validated Prediction Model for All Forms of Acute Coronary Syndrome. JAMA. 2004;291(22):2727–33.
19. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taurus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128(2):141–51.
20. Wagenmakers EJ, Farrell S. AIC model selection using Akaike weights. Psychon Bull Rev. 2004;11(1):192–6.
21. Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, Stone CA, Yu R, Groenendijk L, Groenendijk R, Holmes NE, et al. Development and Validation of a Peni- cilin Allergy Clinical Decision Rule. JAMA Intern Med. 2020;180(5):745–52.
22. Yu Q, Wu Y, Jin Q, Chen Y, Lin Q, Liu X. Development and internal valida- tion of a multivariable prediction model for 6-year risk of stroke: a cohort study in middle-aged and elderly Chinese population. BMJ Open. 2021;11(7):e048734.
23. Liu XJ, Wan ZF, Zhao N, Zhang YP, Mi L, Wang XH, Zhou D, Wu Y, Yuan ZY. Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coro- nary intervention. Cardiovasc Diabetol. 2015;14:110.
24. !!!INVALID CITATION !!!.
26. Zhang S, Wan Z, Zhang Y, Fan Y, Gu W, Li F, Meng L, Zeng X, Han D, Li X. Neutrophil count improves the GRACE risk score prediction of clinical outcomes in patients with ST-elevation myocardial infarction. Atherosclerosis. 2015;241(2):723–8.

27. Carvalho LSF, Bognoi LAC, de Almeida OLR, JOC ES, Nadruz W, Coelho OR, Sposito AC. Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. Eur Heart J Acute Cardiovasc Care. 2019;8(7):643–51.

28. Chattopadhyay S, George A, John J, Sathyapalan T. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes. Eur Heart J. 2018;39(29):2740–5.

29. Lehmann R, Fichtlscherer S, Schachinger V, Held C, Hofer G, Zehnder AM, Spyridopoulos I. Complete revascularization in patients undergoing multivessel PCI is an independent predictor of improved long-term survival. J Interv Cardiol. 2010;23(3):256–63.

30. Hannan EL, Racz M, Holmes DR, King SB, Walford G, Ambrose JA, Sharma S, Katz S, Clark LT, Jones RH. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation. 2006;113(20):2406–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.